The Economics of Peptide Research: Why Trials Lag
Pivotal trials cost millions and patents fund them. Unpatentable peptides break that model — which explains the evidence gap.
A recurring frustration in the peptide world is the thinness of the human evidence. For compounds that thousands of people use, the catalog of large, well-run clinical trials is often nearly empty. It is tempting to read this as a conspiracy or as proof the compounds don’t work. The more accurate explanation is duller and more structural: the economics of drug development simply don’t line up behind most peptides.
Why money doesn’t flow here
Pivotal trials — the rigorous studies regulators require for approval — are expensive. An analysis of the trials supporting US FDA approvals gives a sense of scale.
| Pivotal-trial cost (FDA approvals, 2015–2016) | Estimate |
|---|---|
| Median cost per trial | $19.0 million |
| Interquartile range | $12.2M – $33.1M |
| Uncontrolled trials (mean) | $13.5 million |
| Placebo/active-comparator trials (mean) | $35.1 million |
| Highest single trial | $346.8 million |
Those figures come from Moore and colleagues in JAMA Internal Medicine (2018), who estimated costs for 138 pivotal trials behind 59 novel agents. Pharmaceutical companies fund this kind of spending because, if the drug succeeds, a patent grants years of exclusive sales to recoup the investment. That exclusivity is the engine of the whole system.
Many peptides break this model. Some are old, naturally occurring, or otherwise hard to protect with strong patents. If anyone could manufacture and sell the compound the moment it was approved, no company can justify a multimillion-dollar trial to prove it works. The result is a molecule that may be biologically interesting but is commercially orphaned.
The honest implication: the absence of large trials for a given peptide is often a statement about its patent economics, not a verdict on its biology. That cuts both ways — “no big trials” doesn’t prove it works either.
What tends to fill the vacuum
- Small academic studies, often underpowered and rarely replicated at scale.
- Animal and mechanistic research, which is suggestive but not decisive for humans.
- User anecdote and clinic experience, which is real-world but uncontrolled and prone to bias.
The takeaway
Much of the peptide evidence gap is an economics problem, not a science problem. Definitive trials cost millions — a median near $19 million per pivotal trial, and far more for placebo-controlled designs — and that spending is normally repaid through patent exclusivity. Unpatentable molecules can’t attract it, so the data stay thin even for compounds with genuine promise. The right response is neither cynicism nor faith, but calibrated caution: recognize that “we don’t have the trials” frequently means “no one could profit from running them.”